Literature DB >> 32392457

Challenges of Making Effective Influenza Vaccines.

Sigrid Gouma1, Elizabeth M Anderson1, Scott E Hensley1.   

Abstract

Seasonal influenza vaccines prevent influenza-related illnesses, hospitalizations, and deaths. However, these vaccines are not as effective as other viral vaccines, and there is clearly room for improvement. Here, we review the history of seasonal influenza vaccines, describe challenges associated with producing influenza vaccine antigens, and discuss the inherent difficulties of updating influenza vaccine strains each influenza season. We argue that seasonal influenza vaccines can be dramatically improved by modernizing antigen production processes and developing models that are better at predicting viral evolution. Resources should be specifically dedicated to improving seasonal influenza vaccines while developing entirely new vaccine platforms.

Entities:  

Keywords:  antigenic variation; egg adaptation; immunogenicity; seasonal influenza vaccine; vaccine effectiveness; viral evolution

Mesh:

Substances:

Year:  2020        PMID: 32392457      PMCID: PMC7529958          DOI: 10.1146/annurev-virology-010320-044746

Source DB:  PubMed          Journal:  Annu Rev Virol        ISSN: 2327-056X            Impact factor:   10.431


  116 in total

1.  Predicting evolution from the shape of genealogical trees.

Authors:  Richard A Neher; Colin A Russell; Boris I Shraiman
Journal:  Elife       Date:  2014-11-11       Impact factor: 8.140

2.  Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older.

Authors:  Lisa M Dunkle; Ruvim Izikson; Peter Patriarca; Karen L Goldenthal; Derek Muse; Janice Callahan; Manon M J Cox
Journal:  N Engl J Med       Date:  2017-06-22       Impact factor: 91.245

Review 3.  Live attenuated influenza vaccine (LAIV): recent effectiveness results from the USA and implications for LAIV programmes elsewhere.

Authors:  Richard Pebody; Jim McMenamin; Hanna Nohynek
Journal:  Arch Dis Child       Date:  2017-08-30       Impact factor: 3.791

4.  A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.

Authors:  Emily J Erbelding; Diane J Post; Erik J Stemmy; Paul C Roberts; Alison Deckhut Augustine; Stacy Ferguson; Catharine I Paules; Barney S Graham; Anthony S Fauci
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

5.  Diminished B-Cell Response After Repeat Influenza Vaccination.

Authors:  Mrinmoy Sanyal; Tyson H Holmes; Holden T Maecker; Randy A Albrecht; Cornelia L Dekker; Xiao-Song He; Harry B Greenberg
Journal:  J Infect Dis       Date:  2019-04-19       Impact factor: 5.226

6.  Efficacy of high-dose versus standard-dose influenza vaccine in older adults.

Authors:  Carlos A DiazGranados; Andrew J Dunning; Murray Kimmel; Daniel Kirby; John Treanor; Avi Collins; Richard Pollak; Janet Christoff; John Earl; Victoria Landolfi; Earl Martin; Sanjay Gurunathan; Richard Nathan; David P Greenberg; Nadia G Tornieporth; Michael D Decker; H Keipp Talbot
Journal:  N Engl J Med       Date:  2014-08-14       Impact factor: 91.245

7.  Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial.

Authors:  Benjamin J Cowling; Ranawaka A P M Perera; Sophie A Valkenburg; Nancy H L Leung; A Danielle Iuliano; Yat Hung Tam; Jennifer H F Wong; Vicky J Fang; Athena P Y Li; Hau Chi So; Dennis K M Ip; Eduardo Azziz-Baumgartner; Alicia M Fry; Min Z Levine; Shivaprakash Gangappa; Suryaprakash Sambhara; Ian G Barr; Danuta M Skowronski; J S Malik Peiris; Mark G Thompson
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

Review 8.  Predictive Modeling of Influenza Shows the Promise of Applied Evolutionary Biology.

Authors:  Dylan H Morris; Katelyn M Gostic; Simone Pompei; Trevor Bedford; Marta Łuksza; Richard A Neher; Bryan T Grenfell; Michael Lässig; John W McCauley
Journal:  Trends Microbiol       Date:  2017-10-30       Impact factor: 17.079

9.  The characteristics and antigenic properties of recently emerged subclade 3C.3a and 3C.2a human influenza A(H3N2) viruses passaged in MDCK cells.

Authors:  Yipu Lin; Stephen A Wharton; Lynne Whittaker; Mian Dai; Burcu Ermetal; Janice Lo; Andrea Pontoriero; Elsa Baumeister; Rodney S Daniels; John W McCauley
Journal:  Influenza Other Respir Viruses       Date:  2017-02-28       Impact factor: 4.380

10.  THE ANTIBODY RESPONSE OF HUMAN SUBJECTS VACCINATED WITH THE VIRUS OF HUMAN INFLUENZA.

Authors:  T Francis; T P Magill
Journal:  J Exp Med       Date:  1937-01-31       Impact factor: 14.307

View more
  6 in total

1.  Generation of a live attenuated influenza A vaccine by proteolysis targeting.

Authors:  Longlong Si; Quan Shen; Jing Li; Li Chen; Jinying Shen; Xue Xiao; Haiqing Bai; Tang Feng; Adam Yongxin Ye; Le Li; Chunhe Zhang; Zhen Li; Ping Wang; Crystal Yuri Oh; Atiq Nurani; Siwen Niu; Chengxin Zhang; Xiaoqiong Wei; Wanqiong Yuan; Hao Liao; Xiaojie Huang; Ning Wang; Wen-Xia Tian; Hongwei Tian; Li Li; Xiaoheng Liu; Roberto Plebani
Journal:  Nat Biotechnol       Date:  2022-07-04       Impact factor: 68.164

2.  Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.

Authors:  James D Allen; Ted M Ross
Journal:  J Virol       Date:  2022-03-15       Impact factor: 6.549

3.  Antigenic and virological properties of an H3N2 variant that continues to dominate the 2021-22 Northern Hemisphere influenza season.

Authors:  Marcus J Bolton; Jordan T Ort; Ryan McBride; Nicholas J Swanson; Jo Wilson; Moses Awofolaju; Colleen Furey; Allison R Greenplate; Elizabeth M Drapeau; Andrew Pekosz; James C Paulson; Scott E Hensley
Journal:  Cell Rep       Date:  2022-05-31       Impact factor: 9.995

4.  H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model.

Authors:  Juan Manuel Carreño; Shirin Strohmeier; Ericka Kirkpatrick Roubidoux; Rong Hai; Peter Palese; Florian Krammer
Journal:  mBio       Date:  2020-12-15       Impact factor: 7.867

5.  Prompt Antiviral Action of Pulmonary CD8+ TRM Cells Is Mediated by Rapid IFN-γ Induction and Its Downstream ISGs in the Lung.

Authors:  Lang Jiang; Lu Liu; Miaomiao Zhang; Linxia Zhang; Cuisong Zhu; Qian He; Lilin Ye; Chen Zhao; Zejun Li; Jianqing Xu; Xiaoyan Zhang
Journal:  Front Immunol       Date:  2022-02-22       Impact factor: 7.561

6.  Evaluation of Next-Generation H3 Influenza Vaccines in Ferrets Pre-Immune to Historical H3N2 Viruses.

Authors:  James D Allen; Ted M Ross
Journal:  Front Immunol       Date:  2021-08-12       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.